Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.60% | 144.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.60% | 144.12% | |||
| Cost of Revenue | 3.03% | -- | |||
| Gross Profit | -6.10% | 128.06% | |||
| SG&A Expenses | -34.93% | 82.98% | |||
| Depreciation & Amortization | 1.97% | -5.58% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.26% | 84.64% | |||
| Operating Income | 36.07% | -76.61% | |||
| Income Before Tax | 34.17% | -62.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.17% | -62.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.17% | -62.65% | |||
| EBIT | 36.07% | -76.61% | |||
| EBITDA | 36.71% | -79.33% | |||
| EPS Basic | 37.50% | -43.59% | |||
| Normalized Basic EPS | 37.14% | -52.17% | |||
| EPS Diluted | 37.50% | -43.59% | |||
| Normalized Diluted EPS | 37.14% | -52.17% | |||
| Average Basic Shares Outstanding | 3.47% | 14.89% | |||
| Average Diluted Shares Outstanding | 3.47% | 14.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||